Your session is about to expire
← Back to Search
ESK981 for Kidney Cancer (ERICA Trial)
ERICA Trial Summary
This trial is testing a new drug to see if it is effective in treating kidney cancer when used with another existing drug.
- Kidney Cancer
ERICA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 13 Patients • NCT03456804ERICA Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have received treatment with certain types of antibodies in the past, specifically ones that target PD, PD-L1, CTLA4, IDO, or ESK981.If you have taken medications called mTOR inhibitors or glutaminase inhibitors in the past, you can still participate in the study.You have tumors that have spread to your brain or spinal cord and have not been treated yet.You are allergic to gelatin or lactose monohydrate.You have a history of bleeding problems, such as heavy or abnormal bleeding, within the past 6 weeks before starting the study.You have already received more than one type of medication that targets blood vessel growth in the treatment of metastatic disease.You are able to perform everyday activities with a moderate level of energy and independence.Your organs and bone marrow are working properly.
- Group 1: ESK981 Monotherapy
- Group 2: ESK981 and Nivolumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the FDA's current stance on ESK981?
"ESK981 falls into the category of a Phase 2 trial, which means that while there is evidence of its safety, there are no studies proving its efficacy. Our team rates it as a 2."
Could you provide some context for ESK981's role in medical research?
"747 studies are currently underway to test the efficacy of ESK981 with 82 of them in Phase 3. These trials are being conducted all over the world, but most notably in Basel, BE and 40325 other locations."
Have similar trials been conducted in the past?
"ESK981 has undergone 747 active studies since first being trialed in 2010. These studies have taken place across 2347 different cities and 50 countries. The original study, sponsored by Medarex, only involved 127 patients but it completed Phase 1 of the drug approval process. In the past 10 years, an additional 249 trials have been completed for this medication."
Are there any current vacancies in this clinical trial for new patients?
"2665 other clinical trials for carcinoma, renal cell and 747 studies are still recruiting patients."
What are the medical benefits of ESK981?
"ESK981 is a popular choice for treating malignant neoplasms. However, it has also shown efficacy in managing other conditions like unresectable melanoma, squamous cell carcinoma, and metastatic esophageal adenocarcinoma."
How many people can sign up for this research project?
"This study is not recruiting new patients at the moment, as noted by its posting date of April 11th, 2019 and last update on September 8th, 2021. If you are interested in other trials, 2665 studies for carcinoma, renal cell and 747 for ESK981 are actively looking for participants."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger